Zobrazeno 1 - 10 of 37 pro vyhledávání: '"resectable lung cancer"'
1
Akademický článek
Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
Autor: Rui Fu, Jun Huang, Xiaoru Tian, Chaoyang Liang, Yuanyuan Xiong, Jia‐Tao Zhang, Benyuan Jiang, Song Dong, Yuhua Gong, Wei Gao, Fang Li, Yonglei Shi, Zhentian Liu, Xuan Gao, Rongrong Chen, Wenzhao Zhong, Yi Zhang
Publikováno v: Molecular Oncology, Vol 17, Iss 5, Pp 825-838 (2023)
Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be v
Externí odkaz: https://doaj.org/article/e4f5ea1121974d468711e93147e294cc
Zobrazit plný text záznamu
2
Akademický článek
Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers
Autor: Zhengbo Song, Xiangbin Chen, Yi Shi, Rongfang Huang, Wenxian Wang, Kunshou Zhu, Shaofeng Lin, Minxian Wang, Geng Tian, Jialiang Yang, Gang Chen
Publikováno v: Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 73-83 (2020)
For resectable cancer patients, a method that could precisely predict the risk of postoperative recurrence would be crucial for guiding adjuvant treatment. Since T cell receptor (TCR) repertoires had been shown to be closely related to the dynamics o
Externí odkaz: https://doaj.org/article/96b944fe7ed642d6a8eea0110ce0fab4
Zobrazit plný text záznamu
3
Akademický článek
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
Autor: Ivy Riano, Inas Abuali, Aditya Sharma, Jewelia Durant, Konstantin H. Dragnev
Publikováno v: Pharmaceuticals, Vol 16, Iss 2, p 233 (2023)
The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (NSCLC) is being increasingly adopted, but questions about the most appropriate applications remain. Although patients with resectable NSCLC are often
Externí odkaz: https://doaj.org/article/72dd4b1efd0d4600b39a49583753f762
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers
Autor: Shaofeng Lin, Jialiang Yang, Gang Chen, Yi Shi, Wenxian Wang, Xiangbin Chen, Rongfang Huang, Minxian Wang, Zhengbo Song, Geng Tian, Kunshou Zhu
Publikováno v: Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 73-83 (2020)
Molecular Therapy. Methods & Clinical Development
For resectable cancer patients, a method that could precisely predict the risk of postoperative recurrence would be crucial for guiding adjuvant treatment. Since T cell receptor (TCR) repertoires had been shown to be closely related to the dynamics o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6c0fd83f36107e284faf5c3a4afde20
https://doi.org/10.1016/j.omtm.2020.05.020
Zobrazit plný text záznamu
7
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
Autor: John F. Roller, Nirmal K. Veeramachaneni, Jun Zhang
Publikováno v: Cancers, Vol 14, Iss 741, p 741 (2022)
While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has notably decreased in the past decade. Immunotherapy with immune checkpoint inhibitors have played a noteworthy role in contributing to this improved surv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b83e44b0cd527606a9ecb116e484e8
https://www.mdpi.com/2072-6694/14/3/741
Zobrazit plný text záznamu
8
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Publikováno v: Journal of Thoracic Oncology. 13(12):1818-1831
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________83::b1508adaac7b117792b27269f270956a
https://cris.maastrichtuniversity.nl/en/publications/0f13fbee-2685-468d-ae36-daeff1ba853a
Zobrazit plný text záznamu
10
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Autor: Blumenthal, GM, Bunn, PA, Chaft, JE, McCoach, CE, Perez, EA, Scagliotti, GV, Carbone, DP, Aerts, HJWL, Aisner, DL, Bergh, J, Berry, DA, Jarkowski, A, Botwood, N, Cross, DAE, Diehn, M, Drezner, NL, Doebele, RC, Blakely, CM, Eberhardt, WEE, Felip, E, Gianni, L, Keller, SP, Leavey, PJ, Malik, S, Pignatti, F, Prowell, TM, Redman, MW, Rizvi, NA, Rosell, R, Rusch, V, de Ruysscher, D, Schwartz, LH, Sridhara, R, Stahel, RA, Swisher, S, Taube, JM, Travis, WD, Keegan, P, Wiens, JR, Wistuba, II, Wynes, MW, Hirsch, FR, Kris, MG
Publikováno v: Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2aaad27ec3457b061c95dece9d1928ac
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5308
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje